Host: |
Rabbit |
Applications: |
WB/IHC/IF/ELISA |
Reactivity: |
Human/Rat/Mouse |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Rabbit polyclonal antibody anti-Leukocyte immunoglobulin-like receptor subfamily B member 5 (21-70 aa) is suitable for use in Western Blot, Immunohistochemistry, Immunofluorescence and ELISA research applications. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide. |
Purification: |
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
Concentration: |
1 mg/mL |
Dilution Range: |
WB 1:500-1:2000IHC-P 1:100-1:300ELISA 1:20000IF 1:50-200 |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Gene Symbol: |
LILRB5 |
Gene ID: |
10990 |
Uniprot ID: |
LIRB5_HUMAN |
Immunogen Region: |
21-70 aa |
Specificity: |
CD85c Polyclonal Antibody detects endogenous levels of CD85c protein. |
Immunogen: |
The antiserum was produced against synthesized peptide derived from the N-terminal region of human LILRB5 at the amino acid range 21-70 |
Function | May act as receptor for class I MHC antigens. |
Protein Name | Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 5Cd85 Antigen-Like Family Member CLeukocyte Immunoglobulin-Like Receptor 8Lir-8Cd Antigen Cd85c |
Database Links | Reactome: R-HSA-198933 |
Cellular Localisation | MembraneSingle-Pass Type I Membrane Protein |
Alternative Antibody Names | Anti-Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 5 antibodyAnti-Cd85 Antigen-Like Family Member C antibodyAnti-Leukocyte Immunoglobulin-Like Receptor 8 antibodyAnti-Lir-8 antibodyAnti-Cd Antigen Cd85c antibodyAnti-LILRB5 antibodyAnti-LIR8 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance